| Frank M Chybowski, MD | |
|
1611 S Madison St, Appleton, WI 54915-1844 | |
| (920) 730-5380 | |
| Not Available |
| Full Name | Frank M Chybowski |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1611 S Madison St, Appleton, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487648242 | NPI | - | NPPES |
| 31900300 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 33984 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Frank M Chybowski, MD 1611 S Madison St, Appleton, WI 54915-1844 Ph: (920) 730-5380 | Frank M Chybowski, MD 1611 S Madison St, Appleton, WI 54915-1844 Ph: (920) 730-5380 |
News Archive
Sigma-Aldrich today announced a worldwide licensing agreement with Polyplus-transfection (Strasbourg, France) to manufacture and commercialize Zip Nucleic Acid (ZNA(TM)) oligonucleotides, a new technology that provides solutions for increased affinity for nucleic acids.
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.
Simcyp Limited, experts in simulating how the body deals with new drugs in development, today announces that it has won a Queen's Award for Enterprise. The award has been made in the Innovation category and reflects Simcyp's continuous development of modelling and simulation software for evaluating drugs in the safety of a computer.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
Severely obese patients who undergo gastric bypass surgery significantly reduce their risk of death from coronary heart disease, diabetes, and cancer, according to research published in the Aug. 23, 2007, issue of The New England Journal of Medicine.
› Verified 3 days ago
Michael Small, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1607 N Briarcliff Dr, Appleton, WI 54915 Phone: 920-380-9916 | |
Ronald W Slovick, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1611 S Madison St, Appleton, WI 54915 Phone: 920-730-5380 |